1-2 of 2
single-blind method
Close
Sort by
Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Esther Natalie Oliva, MD, Caterina Alati, MD, Valeria Santini, MD, Antonella Poloni, PhD MD, Marta Riva, MD, Pasquale Niscola, MD PhD, Valentina Giai, MD, Grazia Sanpaolo, MD, Enrico Balleari, Elena Crisà, MD, Dario Ferrero, MD, Ulrich Germing, MD, Pierre Fenaux, MD PhD, Giuseppe A. Palumbo, MD PhD, Prassede Salutari, MD, Stefana Impera, MD, Isabella Capodanno, MD, Gianluigi Reda, MD, Anna Marina Liberati, Alfredo Molteni, MD, Giorgina Specchia, MD, Francesco Buccisano, MD, Maria Teresa Voso, MD, Stefano Mancini, MD, Monica Bocchia, Anna Candoni, MD, Bruno Martino, MD, Patrizia Cufari, Maria Grazia D'Errigo, Gina Zini, MD PhD, Roberto Latagliata
Journal: Blood
Blood (2019) 134 (Supplement_1): 3000.
https://doi.org/10.1182/blood-2019-126744
Published: 2019
Journal Articles

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Esther Natalie Oliva, MD, Valeria Santini, MD, Gina Zini, Giuseppe A Palumbo, Antonella Poloni, MD, Agostino Cortelezzi, MD, Maria Teresa Voso, Alfredo Molteni, Grazia Sanpaolo, MD, Antonio Marino, Filippo Rodà, MD, Caterina Alati, Francesca Ronco, Francesco Di Raimondo, Pietro Leoni, MD, Giuliana Alimena, Silvia Finotto, Roberto Latagliata, MD, Francesco Nobile, MD
Journal: Blood
Blood (2012) 120 (21): 923.
https://doi.org/10.1182/blood.V120.21.923.923
Published: 2012